X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Stemline will have the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Insilico Medicine
Deal Size: $512.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $677.0 million Upfront Cash: $677.0 million
Deal Type: Acquisition June 10, 2020
Details:
With the support of Menarini’s infrastructure, Stemline will continue its efforts to develop new applications of ELZONRIS to meet unmet needs of patients with difficult to treat diseases and cancers.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $677.0 million Upfront Cash: $677.0 million
Deal Type: Acquisition May 04, 2020
Details:
A Phase 1/2 trial of ELZONRIS in combination with other agents in patients with relapsed/refractory AML, treatment-naive AML unfit for chemotherapy, and high-risk myelodysplastic syndrome (MDS) is currently enrolling patients.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
